Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albrecht Stoehr

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
AIDS (London, England)|June 26, 2003
Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphomaChristian Hoffmann, Eva Wolf, Gerd Fätkenheuer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 30, 2026
Resolved HBV Infection Is Not Associated With Liver-Related Outcomes in Survival Analysis of Caucasians After HCV CureLaura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, et al.
AIDS (London, England)|January 20, 2011
N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patientsDaniel A Duprez, Jacqueline Neuhaus, Russell Tracy, et al.
European Journal of Gastroenterology & Hepatology|April 30, 2020
Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-RegistryHolger Hinrichsen, Albrecht Stoehr, Markus Cornberg, et al.
European Journal of Gastroenterology & Hepatology|September 21, 2020
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R)Kerstin Stein, Albrecht Stoehr, Hartwig Klinker, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 21, 2015
Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infectionMalte H Wehmeyer, Sabine Jordan, Stefan Lüth, et al.
Journal of the International AIDS Society|November 15, 2014
Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapyGesa Erdbeer, Michael Sabranski, Ina Sonntag, et al.
AIDS (London, England)|November 26, 2015
CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphomaChristian Hoffmann, Philipp Schommers, Eva Wolf, et al.
Alimentary Pharmacology & Therapeutics|March 16, 2019
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-RegistryThomas Berg, Uwe Naumann, Albrecht Stoehr, et al.
Journal of the International AIDS Society|November 15, 2014
Intermittent viraemia and immune reconstitution in patients with more than 10-15 years of antiretroviral therapy: baseline values still matterGesa Erdbeer, Michael Sabranski, Ina Sonntag, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
AIDS (London, England)|June 26, 2003
Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphomaChristian Hoffmann, Eva Wolf, Gerd Fätkenheuer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 30, 2026
Resolved HBV Infection Is Not Associated With Liver-Related Outcomes in Survival Analysis of Caucasians After HCV CureLaura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, et al.
AIDS (London, England)|January 20, 2011
N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patientsDaniel A Duprez, Jacqueline Neuhaus, Russell Tracy, et al.
European Journal of Gastroenterology & Hepatology|April 30, 2020
Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-RegistryHolger Hinrichsen, Albrecht Stoehr, Markus Cornberg, et al.
European Journal of Gastroenterology & Hepatology|September 21, 2020
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R)Kerstin Stein, Albrecht Stoehr, Hartwig Klinker, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 21, 2015
Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infectionMalte H Wehmeyer, Sabine Jordan, Stefan Lüth, et al.
Journal of the International AIDS Society|November 15, 2014
Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapyGesa Erdbeer, Michael Sabranski, Ina Sonntag, et al.
AIDS (London, England)|November 26, 2015
CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphomaChristian Hoffmann, Philipp Schommers, Eva Wolf, et al.
Alimentary Pharmacology & Therapeutics|March 16, 2019
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-RegistryThomas Berg, Uwe Naumann, Albrecht Stoehr, et al.
Journal of the International AIDS Society|November 15, 2014
Intermittent viraemia and immune reconstitution in patients with more than 10-15 years of antiretroviral therapy: baseline values still matterGesa Erdbeer, Michael Sabranski, Ina Sonntag, et al.
Pageof 6